a carregar...

UC.PT

Imprensa da Universidade

António Abel Garcia Meliço-Silvestre

Docente na Faculdade de Medicina da Universidade de Coimbra. Ensaios Clínicos em Curso: • RESIST 2 (randomized Evaluation of Strategic Intervention in Multi-drug resistant patients with Tripanavir), Randomized, Open-Label, Comparative Safety and Efficacy Study of Tripanavir Boosted with Low Dose Ritonavir (TPV/RTV) versus Genotipically-Defined Protease Inhibitor/ Ritonavir (PI/RTV) in Multiple antirretroviral drug-experienced patients; • Multicentre, open-label pilot study to evaluate the efficacy and safety of HIVID (Zalcitabine DDC) BID regímen in Combination with zidovudine (ZDV) plus Protease Inhibitor (PI) and Lamivudine (3TC) plus zidovudine and PI in HIV-1 Infected Patients – AI 455-110; • Estudo randomizado, em ocultação parcial, multicêntrico, de fase III; com três braços, para avaliação da eficácia e segurança do interferão peguilado alfa-2a em monoterapia versus terapêutica combinada de interferão alfa-2a com ribavirina durante 48 semanas e 24 semanas de seguimento em doentes com hepatite C crónica co-infetada com o vírus da imunodeficiência humana; • APV30005 – an open label phase III study to assess the long-term safety profile of GW433908 containing regimens in HIV1 infected subjects; • A phase III open-label safety study of T-20/RO29-9800 (HIV-1 fusion inhibitor) in combination with oral antiretrovirals, in patients who are unable to constract a viable regimen; • N.º CAL 30001: A Phase III, randomized, open-label, parallel, multicenter study to evaluate treatment with fixed dose combination of abacavir/lamivudine (600mg/300mg) once-daily versus abacavir (300mg) once daily in combination with tenofovir once daily and a new PI or NNRTI for 48 weeks in ART experienced HIV-1 infected patients; • AI424-900 – Atazanavir – (BMS-232632) for HIV – infected individuals: an early access program.

Obras editadas na IUC: 

Orações de Sapiência da Faculdade de Medicina 1845-2000